 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 4 | 1/1 | 返回列表 |
| 查看: 568 | 回復(fù): 3 | |||
[交流]
求高人幫翻譯一段說明書 急~
|
|||
|
1 General Responding patients may not experience an improvement in performance status on therapy and may experience worsening. The relationship between changes in performance status, response to therapy, and treatment-related side effects has not been established. 2 Cutaneous Localized erythema of the extremities with edema followed by desquamation has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended [see Dose Adjustments During Treatment (2.7)]. The discontinuation rate due to skin toxicity was 1.6% (15/965) for metastatic breast cancer patients. Among 92 breast cancer patients premedicated with 3-day corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued TAXOTERE due to skin toxicity. 3 Fluid Retention Severe fluid retention has been reported following TAXOTERE therapy [see Boxed Warning, Premedication Regimen (2.6)]. Patients should be premedicated with oral corticosteroids prior to each TAXOTERE administration to reduce the incidence and severity of fluid retention [see Premedication Regimen (2.6)]. Patients with pre-existing effusions should be closely monitored from the first dose for the possible exacerbation of the effusions. When fluid retention occurs, peripheral edema usually starts in the lower extremities and may become generalized with a median weight gain of 2 kg. Among 92 breast cancer patients premedicated with 3-day corticosteroids, moderate fluid retention occurred in 27.2% and severe fluid retention in 6.5%. The median cumulative dose to onset of moderate or severe fluid retention was 819 mg/m2. 9.8% (9/92) of patients discontinued treatment due to fluid retention: 4 patients discontinued with severe fluid retention; the remaining 5 had mild or moderate fluid retention. The median cumulative dose to treatment discontinuation due to fluid retention was 1021 mg/m2. Fluid retention was completely, but sometimes slowly, reversible with a median of 16 weeks from the last infusion of TAXOTERE to resolution (range: 0 to 42+ weeks). Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). 4 Neurologic Severe neurosensory symptoms (paresthesia, dysesthesia, pain) were observed in 5.5% (53/965) of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%. When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued [see Dose Adjustments During Treatment (2.7)]. Patients who experienced neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 9 weeks from onset (range: 0 to 106 weeks). Severe peripheral motor neuropathy mainly manifested as distal extremity weakness occurred in 4.4% (42/965). 5 Asthenia Severe asthenia has been reported in 14.9% (144/965) of metastatic breast cancer patients but has led to treatment discontinuation in only 1.8%. Symptoms of fatigue and weakness may last a few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease. 6. ADVERSE REACTIONS Adverse reactions are described for TAXOTERE according to indication. 6.1 Clinical Trial Experience • Breast Cancer Monotherapy with TAXOTERE for locally advanced or metastatic breast cancer after failure of prior chemotherapy TAXOTERE 100 mg/m2: Adverse drug reactions occurring in at least 5% of patients are compared for three populations who received TAXOTERE administered at 100 mg/m2 as a 1-hour infusion every 3 weeks: 2045 patients with various tumor types and normal baseline liver function tests; the subset of 965 patients with locally advanced or metastatic breast cancer, both previously treated and untreated with chemotherapy, who had normal baseline liver function tests; and an additional 61 patients with various tumor types who had abnormal liver function tests at baseline. These reactions were described using COSTART terms and were considered possibly or probably related to TAXOTERE. At least 95% of these patients did not receive hematopoietic support. The safety profile is generally similar in patients receiving TAXOTERE for the treatment of breast cancer and in patients with other tumor types (See Table 4). |
回復(fù)此樓» 猜你喜歡
286求調(diào)劑
已經(jīng)有7人回復(fù)
-
290求調(diào)劑
已經(jīng)有5人回復(fù)
-
085600，320分求調(diào)劑
已經(jīng)有6人回復(fù)
-
292分，材料與化工，申請調(diào)劑
已經(jīng)有15人回復(fù)
-
0710生物學(xué)求調(diào)劑
已經(jīng)有4人回復(fù)
-
一志愿北京科技，085601總分305求調(diào)劑
已經(jīng)有5人回復(fù)
-
材料求調(diào)劑
已經(jīng)有4人回復(fù)
-
一志愿西安交大材料學(xué)碩（英一數(shù)二）347，求調(diào)劑到高分子/材料相關(guān)專業(yè)
已經(jīng)有9人回復(fù)
-
材料專碩322分
已經(jīng)有6人回復(fù)
-
070300化學(xué)求調(diào)劑
已經(jīng)有13人回復(fù)
» 搶金幣啦！回帖就可以得到:
-
【招聘】溫州醫(yī)科大學(xué)/附屬醫(yī)院/甌江實(shí)驗(yàn)室李校堃院士團(tuán)隊(duì)誠聘博士后和科研人員
+2/185
-
歡迎報(bào)考贛南師范大學(xué)智能制造與未來能源學(xué)院
+2/142
-
大連工業(yè)大學(xué) 高分子材料 接收考研調(diào)劑
+1/39
-
能源動力專碩（清潔能源技術(shù)）接收調(diào)劑碩士生
+1/38
-
江西理工大學(xué)稀土學(xué)院招材料類碩士研究生，稀土光功能材料方向，非誠勿擾
+1/38
-
武漢紡織大學(xué)全重碩士調(diào)劑
+1/23
-
083100生醫(yī)工，338分求調(diào)劑，本大連理工一志愿北航
+2/10
-
南京林業(yè)大學(xué)化工院有機(jī)合成方向碩士招調(diào)劑
+1/9
-
西安工程大學(xué)能源化工新材料研發(fā)項(xiàng)目組接收2026年計(jì)算機(jī)類調(diào)劑研究生
+1/9
-
哈工大化工學(xué)院李蒙剛課題組招收2026年秋季入學(xué)博士生
+1/8
-
煙臺大學(xué)精準(zhǔn)材料高等研究院26年材料方向研究生招生
+1/7
-
博士招生 | 青島科技大學(xué)（高分子、化學(xué)、材料、力學(xué)、航天、機(jī)電工程、計(jì)算機(jī)仿真）
+1/5
-
本科合工大，一志愿中科大329-085400，可接受跨專業(yè)調(diào)劑，求老師收留
+1/4
-
南開大學(xué)環(huán)境學(xué)院 環(huán)境微生物方向 2026年博士招生（名額1人）
+1/4
-
招收2026年度調(diào)劑碩士研究生
+1/4
-
招收2026級研究生
+1/2
-
青島大學(xué)學(xué)碩調(diào)劑！
+1/2
-
調(diào)劑來這
+1/1
-
長江師范學(xué)院化學(xué)工程方向接收大量調(diào)劑考生
+1/1
-
美國田納西理工 | 人工智能/機(jī)器人/自動駕駛方向（全獎(jiǎng)）
+1/1
3樓2011-04-06 14:46:32
這么長 4樓2011-04-06 15:01:20
簡單回復(fù)
Mally892樓
2011-04-01 16:57
回復(fù)
suibowen2010(金幣+1, 翻譯EPI+1): 嘿嘿 沒有辦法啊 任務(wù)...看的不是很到位 很多話不知道怎么說 所以才來這求助高人啊~ 2011-04-01 19:48:04
ringzhu(翻譯EPI-1): 無效應(yīng)助 2011-04-06 12:41:16
哇！ringzhu(翻譯EPI-1): 無效應(yīng)助 2011-04-06 12:41:16
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 suibowen2010 的主題更新
| 4 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 085600，320分求調(diào)劑 +5 | 大饞小子 2026-04-01 | 6/300 |
|
|---|---|---|---|---|
|
|
[考研] 266分，一志愿電氣工程，本科材料，求材料專業(yè)調(diào)劑 +5 | 哇呼哼呼哼 2026-04-01 | 5/250 |
|
|
[考研] 282求調(diào)劑 +15 | ycy1201 2026-04-01 | 17/850 |
|
|
|
[考研] 一志愿南昌大學(xué)324求調(diào)劑 +10 | hanamiko 2026-04-01 | 10/500 |
|
|
|
[考研] 309求調(diào)劑 +8 | gajsj 2026-03-25 | 10/500 |
|
|
|
[考研] 材料調(diào)劑 +8 | 一樣YWY 2026-03-31 | 8/400 |
|
|
|
[考研] 材料與化工調(diào)劑一志愿大連海事085600，349 +9 | 吃的不少 2026-03-30 | 9/450 |
|
|
|
[考研] 275求調(diào)劑 +7 | waltzh 2026-04-01 | 7/350 |
|
|
|
[考研] 材料調(diào)劑 +10 | Eujd1 2026-03-31 | 11/550 |
|
|
|
[考研] 070300求調(diào)劑306分 +5 | 26要上岸 2026-03-27 | 5/250 |
|
|
|
[考研] 358求調(diào)劑 +3 | 王向陽花 2026-03-31 | 3/150 |
|
|
|
[教師之家] 張雪峰戛然而止的飛馳人生 +3 | yexuqing 2026-03-26 | 4/200 |
|
|
|
[考研] 080200學(xué)碩，機(jī)械工程專業(yè)277分，求帶走！ +4 | 瓶子PZ 2026-03-31 | 4/200 |
|
|
|
[考研] 0856求調(diào)劑 +9 | 楒桉 2026-03-28 | 9/450 |
|
|
|
[考研] 318求調(diào)劑 +10 | 陳晨79 2026-03-30 | 10/500 |
|
|
|
[考研] 總分322求生物學(xué)/生化與分子/生物信息學(xué)相關(guān)調(diào)劑 +6 | 星沉uu 2026-03-26 | 7/350 |
|
|
|
[考研] 269求調(diào)劑 +4 | 我想讀研11 2026-03-31 | 4/200 |
|
|
|
[考研] 一志愿食品科學(xué)與工程083200求調(diào)劑 +4 | XQTJZ 2026-03-30 | 4/200 |
|
|
|
[考研] 342求調(diào)劑 +4 | 加油a李zs 2026-03-26 | 4/200 |
|
|
|
[考研] 295求調(diào)劑 +5 | wei-5 2026-03-26 | 5/250 |
|